NO20064577L - Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander - Google Patents

Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander

Info

Publication number: NO20064577L
Authority: NO; Norway
Prior art keywords: tetrahydronaphthindine; histamine; receptor ligands; derivatives useful; derivatives
Prior art date: 2004-05-12

Application number

NO20064577A

Other languages

English (en)

Norwegian (no)

Inventor

John Paul Mathias

Graham Lunn

Ross Sinclair Strang

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-12

Filing date

2006-10-09

Publication date

2006-11-06

2006-10-09 Application filed by Pfizer filed Critical Pfizer

2006-11-06 Publication of NO20064577L publication Critical patent/NO20064577L/no

Links

239000003446 ligand Substances 0.000 title abstract 2
102000004384 Histamine H3 receptors Human genes 0.000 title 1
108090000981 Histamine H3 receptors Proteins 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical class C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
208000026935 allergic disease Diseases 0.000 abstract 1
230000000172 allergic effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Hydrogenated Pyridines (AREA)

NO20064577A 2004-05-12 2006-10-09 Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander NO20064577L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04291222A EP1595881A1 (de)	2004-05-12	2004-05-12	Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
PCT/IB2005/001267 WO2005111036A1 (en)	2004-05-12	2005-05-06	Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands

Publications (1)

Publication Number	Publication Date
NO20064577L true NO20064577L (no)	2006-11-06

Family

ID=34931096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064577A NO20064577L (no)	2004-05-12	2006-10-09	Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander

Country Status (32)

Country	Link
US (2)	US7557121B2 (de)
EP (2)	EP1595881A1 (de)
JP (1)	JP4084410B2 (de)
KR (1)	KR100908155B1 (de)
CN (2)	CN101798305A (de)
AP (1)	AP2006003786A0 (de)
AR (1)	AR049092A1 (de)
AT (1)	ATE491707T1 (de)
AU (1)	AU2005243403B2 (de)
BR (1)	BRPI0510762A (de)
CA (1)	CA2564201C (de)
CR (1)	CR8747A (de)
DE (1)	DE602005025345D1 (de)
DK (1)	DK1756104T3 (de)
EA (1)	EA010487B1 (de)
EC (1)	ECSP066984A (de)
ES (1)	ES2355572T3 (de)
GE (1)	GEP20084552B (de)
GT (1)	GT200500112A (de)
IL (1)	IL178882A (de)
MA (1)	MA28579B1 (de)
MX (1)	MXPA06013113A (de)
NL (1)	NL1029016C2 (de)
NO (1)	NO20064577L (de)
PA (1)	PA8632801A1 (de)
PE (1)	PE20060312A1 (de)
SV (1)	SV2005002112A (de)
TN (1)	TNSN06369A1 (de)
TW (1)	TW200607506A (de)
UY (1)	UY28895A1 (de)
WO (1)	WO2005111036A1 (de)
ZA (1)	ZA200609111B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6468306B1 (en)	1998-05-29	2002-10-22	Advanced Medical Optics, Inc	IOL for inhibiting cell growth and reducing glare
US7621949B2 (en)	2003-12-09	2009-11-24	Advanced Medical Optics, Inc.	Foldable intraocular lens and method of making
DE602006002894D1 (de)	2005-06-17	2008-11-06	Janssen Pharmaceutica Nv	Naphthyridinverbindungen
US8158673B2 (en)	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
EP1945639A1 (de) *	2005-11-04	2008-07-23	Pfizer Limited	Tetrahydronaphthyridinderivat
WO2007099423A1 (en) *	2006-03-02	2007-09-07	Pfizer Products Inc.	1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JP2009531314A (ja)	2006-03-10	2009-09-03	ニューロジェン・コーポレーション	ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物
CA2655604C (en)	2006-06-23	2016-08-09	Abbott Laboratories	Cyclopropyl amine derivatives
US9108948B2 (en)	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
EP2216023A4 (de) *	2007-11-15	2013-03-13	Takeda Pharmaceutical	Kondensiertes pyridinderivat und seine verwendung
WO2009082698A1 (en) *	2007-12-21	2009-07-02	Abbott Laboratories	Compositions for treatment of cognitive disorders
US8383657B2 (en)	2007-12-21	2013-02-26	Abbott Laboratories	Thiazolylidine urea and amide derivatives and methods of use thereof
EA201001329A1 (ru) *	2008-02-22	2011-04-29	Айрм Ллк	Соединения и композиции в качестве модуляторов активности gpr119
JP2011518127A (ja) *	2008-03-31	2011-06-23	エヴォテック・アクチエンゲゼルシャフト	ヒスタミンｈ３受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
WO2010026113A1 (en) *	2008-09-03	2010-03-11	Evotec Neurosciences Gmbh	Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010052222A1 (en) *	2008-11-07	2010-05-14	Evotec Neurosciences Gmbh	(dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
EP2421863A1 (de) *	2009-04-21	2012-02-29	NeuroSearch AS	Substituierte naphthyridinderivate und deren medizinische verwendung
US9186353B2 (en)	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
US8711772B2 (en) *	2009-05-22	2014-04-29	Qualcomm Incorporated	Paging of a user equipment (UE) within a wireless communications system
US20120101106A1 (en) *	2009-07-09	2012-04-26	Mercer Swati P	Tetrahydronapthyridine Orexin Receptor Antagonists
WO2012037258A1 (en)	2010-09-16	2012-03-22	Abbott Laboratories	Processes for preparing 1,2-substituted cyclopropyl derivatives
CN102093356B (zh) *	2011-03-16	2012-12-19	无锡美克赛医药科技有限公司	一种2-氯-5,6,7,8-四氢-1,6-萘啶盐酸盐的制备方法
WO2012131539A1 (en)	2011-03-31	2012-10-04	Pfizer Inc.	Novel bicyclic pyridinones
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
JP6043355B2 (ja)	2011-08-31	2016-12-14	ファイザー・インク	ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
ES2585262T3 (es)	2012-05-04	2016-10-04	Pfizer Inc	Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
MD20140130A2 (ro)	2012-06-29	2015-04-30	Pfizer Inc.	4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
CA2882389A1 (en)	2012-09-20	2014-03-27	Pfizer Inc.	Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
WO2014091352A1 (en)	2012-12-11	2014-06-19	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en)	2012-12-19	2017-10-24	Pfizer Inc.	Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en)	2013-02-13	2014-08-21	Pfizer Inc.	HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AP2015008663A0 (en)	2013-02-19	2015-08-31	Pfizer	Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
AP2015008843A0 (en)	2013-05-02	2015-11-30	Pfizer	Imidazo-triazine derivatives as pde10 inhibitors
CA2925743C (en)	2013-10-04	2018-03-06	Pfizer Inc.	Novel bicyclic pyridinones as gamma-secretase modulators
WO2015092592A1 (en)	2013-12-17	2015-06-25	Pfizer Inc.	Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
PE20161364A1 (es)	2014-04-01	2016-12-25	Pfizer	CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
CR20160455A (es)	2014-04-10	2016-12-16	Pfizer	2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
EP3172210B1 (de)	2014-07-24	2020-01-15	Pfizer Inc	Pyrazolopyrimidin verbindungen
SG11201700243YA (en)	2014-08-06	2017-02-27	Pfizer	Imidazopyridazine compounds
TN2017000342A1 (en)	2015-02-03	2019-01-16	Pfizer	Novel cyclopropabenzofuranyl pyridopyrazinediones
KR20180011272A (ko) *	2015-05-28	2018-01-31	세라밴스 바이오파마 알앤디 아이피, 엘엘씨	Jak 키나제 저해제로서 나프티리딘 화합물
ES2832893T3 (es)	2015-06-17	2021-06-11	Pfizer	Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CN108137586B (zh)	2015-09-14	2021-04-13	辉瑞大药厂	作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
EP3353174A1 (de)	2015-09-24	2018-08-01	Pfizer Inc	N-[2-(3-amino-2,5-dimethyl-1,1-dioxid-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)]-1,3-thiazol-4-yl-amide als bace-hemmer
WO2017051276A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018531924A (ja)	2015-09-24	2018-11-01	ファイザー・インク	テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
PL3419979T3 (pl)	2016-02-23	2020-06-29	Pfizer Inc.	Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
HUE054857T2 (hu)	2016-07-01	2021-10-28	Pfizer	5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
WO2018163066A1 (en)	2017-03-10	2018-09-13	Pfizer Inc.	Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
WO2018163030A1 (en)	2017-03-10	2018-09-13	Pfizer Inc.	Cyclic substituted imidazo[4,5-c]quinoline derivatives
EP3634978A1 (de)	2017-06-07	2020-04-15	Adrx, Inc.	Tau-aggregationshemmer
CN110944998B (zh)	2017-06-22	2022-08-16	辉瑞大药厂	二氢-吡咯并-吡啶衍生物
EP3668886A2 (de)	2017-08-18	2020-06-24	Adrx, Inc.	Peptidinhibitoren der tau-aggregation
ES2942837T3 (es)	2018-03-23	2023-06-07	Pfizer	Derivados de azaespiro piperazina
WO2022182658A1 (en)	2021-02-23	2022-09-01	Hoth Therapeutics, Inc.	Use of aprepitant for treating alzheimer's disease
KR20240012534A (ko) *	2021-05-21	2024-01-29	청두 바이위 파머수티컬 씨오., 엘티디	피페라진 유도체 및 이의 의학적 용도
WO2025145091A1 (en)	2023-12-29	2025-07-03	Pfizer Inc.	Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU709611B2 (en)	1996-02-09	1999-09-02	James Black Foundation Limited	Histamine h3 receptor ligands
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
GB9803536D0 (en) *	1998-02-19	1998-04-15	Black James Foundation	Histamine H,receptor ligands
EP0982300A3 (de)	1998-07-29	2000-03-08	Societe Civile Bioprojet	Alkylamine ohne Imidazolring als Histamin-H3-antagonisten und deren therapeutische Anwendung
TWI298068B (en) *	2000-06-21	2008-06-21	Dainippon Sumitomo Pharma Co	Pharmaceutical composition for schizophrenia
JP4516717B2 (ja)	2000-07-13	2010-08-04	アボット・ラボラトリーズ	ヒスタミン−３受容体リガンドとしての１，３−二置換ピロリジン及び１，３，３−三置換ピロリジン並びにそれらの治療的応用
KR100852362B1 (ko)	2000-08-08	2008-08-14	오르토-맥네일 파마슈티칼, 인코퍼레이티드	비-이미다졸 아릴옥시피페리딘
ATE319696T1 (de) *	2000-08-08	2006-03-15	Ortho Mcneil Pharm Inc	Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
WO2002076925A2 (en)	2001-03-23	2002-10-03	Eli Lilly And Company	Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0206033D0 (en) *	2002-03-14	2002-04-24	Pfizer Ltd	Compounds useful in therapy
CA2532236C (en) *	2003-07-29	2011-08-23	Novo Nordisk A/S	Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
EP1945639A1 (de) *	2005-11-04	2008-07-23	Pfizer Limited	Tetrahydronaphthyridinderivat

2004
- 2004-05-12 EP EP04291222A patent/EP1595881A1/de not_active Withdrawn
2005
- 2005-05-06 KR KR1020067023573A patent/KR100908155B1/ko not_active Expired - Fee Related
- 2005-05-06 WO PCT/IB2005/001267 patent/WO2005111036A1/en not_active Ceased
- 2005-05-06 ES ES05736116T patent/ES2355572T3/es not_active Expired - Lifetime
- 2005-05-06 GE GEAP20059701A patent/GEP20084552B/en unknown
- 2005-05-06 AU AU2005243403A patent/AU2005243403B2/en not_active Ceased
- 2005-05-06 EP EP05736116A patent/EP1756104B1/de not_active Expired - Lifetime
- 2005-05-06 EA EA200601897A patent/EA010487B1/ru not_active IP Right Cessation
- 2005-05-06 DE DE602005025345T patent/DE602005025345D1/de not_active Expired - Lifetime
- 2005-05-06 MX MXPA06013113A patent/MXPA06013113A/es active IP Right Grant
- 2005-05-06 JP JP2007512575A patent/JP4084410B2/ja not_active Expired - Fee Related
- 2005-05-06 CN CN201010150783A patent/CN101798305A/zh active Pending
- 2005-05-06 AT AT05736116T patent/ATE491707T1/de not_active IP Right Cessation
- 2005-05-06 CN CN2005800150008A patent/CN1950371B/zh not_active Expired - Fee Related
- 2005-05-06 CA CA2564201A patent/CA2564201C/en not_active Expired - Fee Related
- 2005-05-06 DK DK05736116.4T patent/DK1756104T3/da active
- 2005-05-06 BR BRPI0510762-8A patent/BRPI0510762A/pt not_active IP Right Cessation
- 2005-05-06 AP AP2006003786A patent/AP2006003786A0/xx unknown
- 2005-05-11 NL NL1029016A patent/NL1029016C2/nl not_active IP Right Cessation
- 2005-05-11 AR ARP050101916A patent/AR049092A1/es unknown
- 2005-05-11 TW TW094115276A patent/TW200607506A/zh unknown
- 2005-05-12 UY UY28895A patent/UY28895A1/es not_active Application Discontinuation
- 2005-05-12 PE PE2005000533A patent/PE20060312A1/es not_active Application Discontinuation
- 2005-05-12 US US11/128,804 patent/US7557121B2/en not_active Expired - Fee Related
- 2005-05-12 SV SV2005002112A patent/SV2005002112A/es not_active Application Discontinuation
- 2005-05-12 PA PA20058632801A patent/PA8632801A1/es unknown
- 2005-05-12 GT GT200500112A patent/GT200500112A/es unknown
2006
- 2006-10-09 NO NO20064577A patent/NO20064577L/no not_active Application Discontinuation
- 2006-10-26 IL IL178882A patent/IL178882A/en not_active IP Right Cessation
- 2006-11-01 ZA ZA200609111A patent/ZA200609111B/xx unknown
- 2006-11-09 EC EC2006006984A patent/ECSP066984A/es unknown
- 2006-11-10 TN TNP2006000369A patent/TNSN06369A1/fr unknown
- 2006-11-10 CR CR8747A patent/CR8747A/es unknown
- 2006-11-10 MA MA29447A patent/MA28579B1/fr unknown
2009
- 2009-06-25 US US12/491,370 patent/US20090258861A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE602005025345D1 (de)	2011-01-27
EP1756104B1 (de)	2010-12-15
DK1756104T3 (da)	2011-02-21
US20090258861A1 (en)	2009-10-15
CR8747A (es)	2006-12-05
EP1595881A1 (de)	2005-11-16
ATE491707T1 (de)	2011-01-15
KR100908155B1 (ko)	2009-07-16
WO2005111036A1 (en)	2005-11-24
TW200607506A (en)	2006-03-01
IL178882A0 (en)	2007-03-08
GEP20084552B (en)	2008-11-25
UY28895A1 (es)	2005-12-30
JP2007536374A (ja)	2007-12-13
ECSP066984A (es)	2006-12-29
CA2564201A1 (en)	2005-11-24
CN1950371A (zh)	2007-04-18
EP1756104A1 (de)	2007-02-28
US20050256135A1 (en)	2005-11-17
CA2564201C (en)	2011-01-18
KR20070014174A (ko)	2007-01-31
US7557121B2 (en)	2009-07-07
JP4084410B2 (ja)	2008-04-30
NL1029016C2 (nl)	2006-05-30
NL1029016A1 (nl)	2005-11-15
BRPI0510762A (pt)	2007-11-20
MA28579B1 (fr)	2007-05-02
CN101798305A (zh)	2010-08-11
PA8632801A1 (es)	2006-06-02
PE20060312A1 (es)	2006-05-03
EA010487B1 (ru)	2008-10-30
AU2005243403A1 (en)	2005-11-24
MXPA06013113A (es)	2007-02-28
AP2006003786A0 (en)	2006-10-31
ZA200609111B (en)	2008-08-27
CN1950371B (zh)	2011-01-12
SV2005002112A (es)	2005-12-13
TNSN06369A1 (fr)	2008-02-22
AR049092A1 (es)	2006-06-28
EA200601897A1 (ru)	2007-02-27
ES2355572T3 (es)	2011-03-29
AU2005243403B2 (en)	2010-10-07
IL178882A (en)	2011-03-31
GT200500112A (es)	2005-12-12

Legal Events

Date	Code	Title	Description
2012-12-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20066055L (no)	2007-01-24	Pyridinderivater
NO20084005L (no)	2008-09-19	Aminderivater
NO20050828L (no)	2005-04-05	lndol-3-svovelderivater
NO20062983L (no)	2006-07-24	Sulfonamid-derivater for behandling av sykdommer
NO20063761L (no)	2006-10-23	Sulfonamidderivater for behandling av sykdommer
NO20060774L (no)	2006-04-06	Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
NO20072978L (no)	2007-06-27	Nye betuinderivater, preparat derav og anvendelse derav
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TW200607506A (en)	2006-03-01	Tetrahydronaphthyridine derivatives
NO20075624L (no)	2007-11-28	Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
WO2006005609A3 (de)	2006-03-16	Substituierte oxindol-derivate und diese enthaltende arzneimittel
NO20070249L (no)	2007-02-15	Pyrrazolo-pyrimidin derivater
NO20080408L (no)	2008-03-25	Azaindazolforbindelser og anvendelse derav
DE60334015D1 (de)	2010-10-14	Pyridopyrrolizin- und pyridoindolizinderivate
NO20072371L (no)	2007-07-12	Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
DE60237528D1 (de)	2010-10-14	Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
NO20071140L (no)	2007-04-19	Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
TW200505862A (en)	2005-02-16	2-amino-pyridine derivatives useful for the treatment of diseases
NO20062020L (no)	2006-07-10	1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
PL1756086T3 (pl)	2008-11-28	Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5
NO20055854L (no)	2006-02-10	(2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
WO2005060959A8 (en)	2006-01-12	Pyrazole derivatives and use thereof as orexin receptor antagonists
NO20065327L (no)	2006-12-18	Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
EA200601462A1 (ru)	2007-04-27	Соединения для лечения заболеваний
NO20062491L (no)	2006-09-06	Benzoksazinderivter og deres anvendelse